Trastuzumab deruxtecan plus pertuzumab improved systemic and intracranial outcomes in HER2-positive breast cancer with baseline brain metastases.
News|Videos|January 9, 2025
Real-World Head-to-Head Analyses Comparing Different Treatment Options For metastatic Castration-Sensitive Prostate Cancer
Sponsored Content: Benjamin H. Lowentritt, MD, FACS reviews Real-World Head-to-Head Analyses Comparing Different Treatment Options For metastatic Castration-Sensitive Prostate Cancer
Advertisement
This educational activity is brought to you by Janssen Biotech, Inc., and is not certified for continuing medical education. The consultant has been paid an honorarium by Janssen Biotech, Inc. The speaker is presenting on behalf of Janssen and must present information in compliance with the U.S. Food and Drug Administration (FDA) requirements applicable to Janssen.
Advertisement
Related to this article
Petosemtamab plus pembrolizumab cut the risk of death by 50% in first-line PD-L1–positive recurrent or metastatic head and neck squamous cell carcinoma.
Relacorilant plus nab-paclitaxel and bevacizumab produced a 59% response rate in platinum-resistant ovarian cancer in Part A of the BELLA trial.
Updated ASTRO recommendations favor moderate hypofractionation for all risk groups and establish 5-fraction ultrahypofractionation as a standard option in localized prostate cancer.
Updated GOBLET cohort 4 data showed a median DOR of about 15 months with pelareorep plus atezolizumab in second-line or later anal cancer.
Firmonertinib demonstrated durable antitumor activity in patients with EGFR PACC-mutated NSCLC in a phase 1b trial.
The IMpactMF trial is being discontinued after an IDMC advised that imetelstat was unlikely to improve OS in relapsed/refractory myelofibrosis.
Sac-TMT plus pembrolizumab prolonged PFS over chemoimmunotherapy in PD-L1–negative nonsquamous lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
Petosemtamab Plus Pembrolizumab Hits Phase 3 OS, ORR Primary End Points in PD-L1+ R/M HNSCC
2
T-DXd Plus Pertuzumab Improves Outcomes in HER2+ Breast Cancer With Brain Metastases
3
Relacorilant Plus Nab-Paclitaxel and Bevacizumab Yields Clinically Meaningful in Platinum-Resistant Ovarian Cancer
4
ASTRO Guideline Backs Hypofractionation Across Risk Groups in Localized Prostate Cancer
5